Cas:130371-64-1 3-(5-methyl-1,2-oxazol-3-yl)-3-oxopropanenitrile manufacturer & supplier

We serve Chemical Name:3-(5-methyl-1,2-oxazol-3-yl)-3-oxopropanenitrile CAS:130371-64-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-(5-methyl-1,2-oxazol-3-yl)-3-oxopropanenitrile

Chemical Name:3-(5-methyl-1,2-oxazol-3-yl)-3-oxopropanenitrile
CAS.NO:130371-64-1
Synonyms:3-(5-methyl-1,2-oxazol-3-yl)-3-oxopropanenitrile
Molecular Formula:C7H6N2O2
Molecular Weight:150.13500
HS Code:2934999090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:66.89000
Exact Mass:150.04300
LogP:1.07938

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-(5-methyl-1,2-oxazol-3-yl)-3-oxopropanenitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(5-methyl-1,2-oxazol-3-yl)-3-oxopropanenitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(5-methyl-1,2-oxazol-3-yl)-3-oxopropanenitrile Use and application,3-(5-methyl-1,2-oxazol-3-yl)-3-oxopropanenitrile technical grade,usp/ep/jp grade.


Related News: The inhaled version was also found to trigger neutralising antibodies and T cell responses after one dose. 5,5,7-trihydroxy-4-trioxidaneyl-45,54,73,84,93-nonaoxid-8-yn-4-one manufacturers For seniors most in need of care, high-quality health care often is beyond reach. ChenMed brings concierge-style medicine — and better health outcomes — to the neediest populations. Physician-led and privately owned, ChenMed is a provider of choice for some 20 Medicare Advantage health insurance plans. 3-[2-(2-methyl-5-nitro-imidazol-1-yl)-ethyl]-1H-quinazoline-2,4-dione suppliers Biogen hiked its revenue guidance for the year, saying it expects total sales of $10.65 billion to $10.85 billion this year. That’s up from its previous estimates of $10.45 billion to $10.75 billion. The new forecast assumes “modest” revenue from Aduhelm in 2021, ramping up thereafter, the company said. tetra-tert-butyl ((5S,5’S)-(hexane-1,6-diylbis(azanediyl))bis(6-oxohexane-6,1,5-triyl))tetracarbamate vendor & factory.